Hisamitsu Pharmaceutical CoFSE:4530 89 Gross Margin % is 58.48% as of Nov. 2025, which is 2% below its 10-year median of 59.69. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 938 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 67.16% on this metric.
Hisamitsu Pharmaceutical Co (FSE:4530) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hisamitsu Pharmaceutical Co had a gross margin of 58.48% for the quarter that ended in Nov. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Hisamitsu Pharmaceutical Co Gross Margin % Related Terms
Hisamitsu Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Gross Margin % of 58.48% as of Nov. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is near median its historical median of 59.69. Over the past decade, Hisamitsu Pharmaceutical Co's Gross Margin % has ranged from 55.73 to 63.57. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #308 out of 938 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Hisamitsu Pharmaceutical Co's Gross Margin % too high?
Hisamitsu Pharmaceutical Co's current Gross Margin % of 58.48% is near median its 10-year median of 59.69. Over the past 10 years, this metric has ranged from a low of 55.73 to a high of 63.57. The Drug Manufacturers industry median Gross Margin % is 48.44. Hisamitsu Pharmaceutical Co's value of 58.48% is 20.7% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #308 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #308 out of 938 companies for Gross Margin %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median Gross Margin % is 48.44. Hisamitsu Pharmaceutical Co's value of 58.48% is 20.7% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Gross Margin % has ranged from 55.73 to 63.57 over the past decade. While the company's 10-year median is 59.69 vs. the industry median of 48.44, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Gross Margin % of 58.48% is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Gross Margin % is 58.48%, which is near median its own 10-year median of 59.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Gross Margin % of 58.48%. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Gross Margin % is 58.48%, which is near median its 10-year median of 59.69 and 20.7% above the Drug Manufacturers industry median of 48.44. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Gross Margin % is 58.48% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Gross Margin %: 58.48% (near median its 10-year median of 59.69)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 20.7% above the Drug Manufacturers median (#308 of 938)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
